From Evidence Architecture to CE-Model Readiness: What Belgian and Dutch Market Access Teams Should Do (Part 1) 

From Evidence Architecture to CE-Model Readiness: What Belgian and Dutch Market Access Teams Should Do (Part 1) 

Picture of Jean-Etienne Poirrier PhD

Jean-Etienne Poirrier PhD

Director, Evidence and HEOR, Belgium

Picture of Melanie van Riemsdijk PhD

Melanie van Riemsdijk PhD

Director, Market Access Benelux

Picture of Sven Tops

Sven Tops

Chief Market
Access Officer

Part 1 of 2: Why the EU Joint Clinical Assessment of orphan medicines is the moment to start building the evidence needed for Belgian and Dutch economic evaluation

The EU Joint Clinical Assessment (JCA) is changing not only how clinical evidence is assessed in Europe, but also how it should be planned to remain relevant for national health economic evaluation. JCA already applies to oncology medicines and advanced therapy medicinal products (ATMPs); from 13 January 2028, it will also apply to orphan medicinal products [1], the focus of this article.

Our starting point is Evidence Architecture: the deliberate design of evidence across the full development pathway, from early clinical development through regulatory approval and health technology assessment (HTA) to national reimbursement, as argued by Kintiga’s Prof. Matthias Schönermark in The Evidence We Never Designed [2]. Rather than asking at submission how to make the best use of the available evidence, we should ask much earlier what future decision-makers will need.

For an orphan medicine filing its marketing authorisation application in 2028, decisions on trial protocols, endpoints, comparators, data collection and registries are being made today and will determine what JCA can assess. Yet JCA does not assess cost-effectiveness: economic evaluation, budget impact, pricing and reimbursement remain national responsibilities. Belgian and Dutch Market Access and Health Economic teams should therefore be involved early, rather than waiting for the Joint Clinical Assessment Report.

The objective is not to build Belgian or Dutch economic models years in advance, but to ensure that the evidence generated for approval and JCA can support the models needed locally. We identify five JCA workstreams that should be made “model-ready” today.

What JCA covers—and why orphan medicines raise the stakes

JCA provides a harmonised European assessment of the relative clinical effectiveness and safety of a health technology. The JCA Subgroup consolidates Member State needs into an assessment scope expressed as PICO questions (Population, Intervention, Comparators, Outcomes), after which the developer submits the relevant clinical evidence and comparative analyses [1,3]. It does not provide an overall judgement of added value, only relative effects and the certainty of the evidence [1].

What lies outside JCA is equally important. In Belgium, cost-effectiveness is an assessment criterion for Class 1 medicines claiming added therapeutic value and soon also for Orphan medicinal products; in the Netherlands, pharmacoeconomic evidence is required for certain reimbursement applications and may inform price negotiations [5]. JCA is therefore a foundation for national HTA, not a substitute. The time lost between a JCA Report and a national submission is largely spent rebuilding the evidence. HEOR teams should therefore anticipate JCA, cost-effectiveness, budget impact and negotiation requirements simultaneously rather than sequentially.

For orphan medicines, this matters even more. They combine small, heterogeneous populations, incomplete natural-history data, single-arm pivotal studies and the need for long-term follow-up. JCA guidance states that rarity does not justify disregarding uncertainty [6], and Belgium’s 2025 guidelines add that rarity is not an argument against economic evaluation and that weak or absent evidence on key variables such as relative treatment effect may make an evaluation hypothetical [4]. In the Netherlands, the government confirmed in May 2026 that it sees no need for a separate orphan reimbursement route; manufacturers remain responsible for demonstrating effectiveness [7]. Between 2023 and 2025, 34% of the medicines assessed by Zorginstituut Nederland (ZIN) were orphan medicines, about 90% were judged effective, and for half of those the institute advised a price negotiation [8]. The Evidence Architecture of an orphan medicine therefore needs to be built early.

Five JCA workstreams to make “model-ready” today

Each workstream below answers three questions: what the JCA needs, what your model will also need, and a hint of what Belgian and Dutch assessors expect. In Part 2 of this series, we will cover those national rules in detail. 

  1. PICO anticipation: define your model’s scope early

JCA requirement: The JCA Subgroup consolidates Member State needs into the lowest feasible number of PICO sets [3,9], which can still be substantial: in the recent JCA of intrathecal onasemnogene abeparvovec (Itvisma), twelve PICO questions remained after scoping [10]. Developers can anticipate the scope through PICO simulation, Joint Scientific Consultation and early expert and patient dialogue.

Model-ready requirement: Assess each PICO for its model implications: comparators as model alternatives, subpopulations as subgroup analyses, and outcomes mapped to the parameters they can inform. This shows early whether JCA evidence can support modelling or whether additional evidence is needed.

Implications for Belgium and the Netherlands: Belgium expects comparison with routine care and relevant, potentially more cost-effective alternatives, including evidence-based off-label treatments [4]. The Netherlands expects comparison with the relevant standard intervention; its 2024 guideline describes fully incremental analysis for multiple alternatives, although ZIN does not yet make it mandatory [11]. Local care pathways should be mapped alongside PICO anticipation.

  1. Systematic literature review: search once, use twice

JCA requirement: Comprehensive and reproducible identification of relevant published and unpublished clinical evidence and ongoing studies, with a search cut-off no more than three months before dossier submission [1,3].

Model-ready requirement: Modelling also needs evidence on economic evaluations, utilities, costs, resource use, epidemiology and natural history. Plan these streams within one coordinated review strategy, with parallel searches and updates timed before each JCA and national submission.

Implications for Belgium and the Netherlands: Belgian and Dutch guidelines both require transparent and reproducible evidence identification [4,11]. Because the JCA search cut-off may be no more than three months before dossier submission [3], review updates should be planned ahead of the JCA and national submissions rather than run as separate exercises. 

  1. Indirect treatment comparisons: build the model’s treatment effect

JCA requirement: Comparative analyses follow HTA Coordination Group guidance for direct and indirect comparisons, with explicit consideration of effect modifiers, population differences, assumptions and potential bias [12].

Model-ready requirement: JCA comparisons often underpin the model’s relative treatment effect, yet models must extrapolate over a much longer horizon. The Itvisma JCA illustrates the challenge: matching-adjusted indirect comparisons reduced the effective sample size by approximately 40% against nusinersen and 63–67% against risdiplam, and network meta-regression did not remove concerns around comparability and overlap [10]. Effect modifiers should therefore be anticipated and collected consistently before database lock.

Implications for Belgium and the Netherlands: Belgian guidelines do not accept expert opinion as a sufficient basis for key effectiveness inputs such as relative treatment effects; the model may then be considered hypothetical [4]. The Dutch 2024 guideline covers indirect comparisons and gives additional guidance on expert opinion and expert elicitation [11]. Expert elicitation can support comparator selection, resource-use assumptions and validation, but reliable comparative evidence must be planned early.

  1. Outcomes and quality of life: plan for national utilities

JCA requirement: JCA focuses on patient-relevant outcomes; where surrogate outcomes are used, their relationship with the final patient outcome must be adequately supported and the uncertainty described [13].

Model-ready requirement: Utilities require quality-of-life data valued with country-specific preferences. Retain item-level EQ-5D responses, not only an index based on one country’s value set, so each HTA agency’s tariff can be applied. Consider EQ-5D-Y for children and caregiver quality of life in rare diseases.

Implications for Belgium and the Netherlands: Belgium recommends EQ-5D-5L for adults with Belgian population preferences [4]. The Dutch reference case likewise uses EQ-5D-5L with the Dutch tariff and may include informal caregivers’ costs and quality-of-life effects where material and methodologically justified [11].

  1. Real-world evidence: prepare for post-launch data and managed entry

JCA requirement: Non-randomised or external-control evidence must demonstrate population comparability, control of confounding, data quality and methodological robustness [12]. Natural-history and registry data can contribute if registry-based studies meet standards for data quality, governance and methodology [14].

Model-ready requirement: Models need local baseline risks, resource use, treatment duration and long-term outcomes. Identify which parameters post-launch real-world evidence could inform, so that outcomes and data sources for potential managed entry agreements are defined before launch.

Implications for Belgium and the Netherlands: Belgium’s reimbursement reform roadmap envisages evidence-focused managed entry and an independent Real-World Evidence Platform; implementation remains staged [15]. In the Netherlands, orphan-drug arrangements following a positive package assessment may include registry-based data collection, monitoring and evaluation [16]. The government intends to discontinue the separate conditional-admission route for orphan medicines and is developing a separate ultra-orphan route whose scope is not yet finalised [7].

What now? Start before the PICO anticipation

JCA will not build your cost-effectiveness model, but it will determine whether you have the evidence to build a credible one within national HTA timelines. For orphan medicines entering JCA from 2028, the planning window is already open: Global and Belgian and Dutch teams should align early, ideally before JCA scoping, database lock and finalisation of registry protocols. Three questions matter most:

  1. Which comparators will Belgian and Dutch assessors expect—and will the evidence generated for JCA support those comparisons?
  2. Will the trial and registry programme provide the evidence needed for utilities, long-term extrapolation and, where relevant, post-launch evidence generation or managed entry agreements?
  3. Who owns the link between the JCA evidence strategy and the Belgian and Dutch economic models?

At Kintiga, our local Market Access and HEOR teams work as one integrated team on exactly these questions: we assess your JCA evidence plan for model readiness and develop the model alongside JCA preparation, adapted for Belgium and the Netherlands. Contact us to discuss your asset!

Coming in Part 2: What Belgium’s 2025 KCE guidelines and RIZIV-INAMI reforms, together with the Netherlands’ 2024 ZIN guideline and evolving medicines-access policies, mean for the economic evaluation of orphan medicines.

Bibliography 

  1. Schönermark, U.P.D.M. The Evidence We Never Designed: Why Europe Must Rethink Rare Disease Innovation. 2026; Available from: https://kintiga.com/the-evidence-we-never-designed-why-europe-must-rethink-rare-disease-innovation/.
  2. Directorate-General for Health and Food Safety, Regulation (EU) 2021/2282 on health technology assessment. 2021.
  3. Neyt, M., N. Thiry, and I. Cleemput, Belgian guidelines for economic evaluations and budget impact analyses: third edition. 2025, Belgian Health Care Knowledge Centre (KCE): Brussels.
  4. Brokkelkamp, D., et al., Use and Outcomes of Cost-Effectiveness Analyses and Additional Considerations in Pharmaceutical Reimbursement in the Netherlands. PharmacoEconomics, 2026. 44(10): p. 1267–1280.
  5. Richter, N. JCA Meets AMNOG: German Benefit Assessments for Tarlatamab and Lurbinectedin Published. 2026  7 October 2026]; Available from: https://kintiga.com/jca-meets-amnog-german-benefit-assessments-for-tarlatamab-and-lurbinectedin-published/.
  6. Directorate-General for Health and Food Safety, Guidance on the validity of clinical studies for joint clinical assessments. 2024.
  7. Hermans, S.T.M., Nr. 976, BRIEF VAN DE MINISTER VAN VOLKSGEZONDHEID, WELZIJN EN SPORT, T.K.d. Staten-Generaal, Editor. 2026.
  8. Onbekend, ‘Zorginstituut wint tijd met beoordelen dure geneesmiddelen’, in Pharmaceutisch Weekblad. 2026.
  9. Directorate-General for Health and Food Safety, Guidance on the scoping process. 2024.
  10. Schönermark, U.P.D.M. When Better Models Meet Missing Overlap. 2026; Available from: https://kintiga.com/when-better-models-meet-missing-overlap/.
  11. Directorate-General for Health and Food Safety, Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons. 2024.
  12. Directorate-General for Health and Food Safety, Guidance on outcomes for joint clinical assessments. 2024.
  13. Boyd, M. NICE Updates its Approach with a New Relevant EQ-5D-5L Dataset: What Does the Change Mean for Patient Access and how Should Companies Prepare? 2026; Available from: https://kintiga.com/nice-updates-its-approach-with-a-new-relevant-eq-5d-5l-dataset-what-does-the-change-mean-for-patient-access-and-how-should-companies-prepare/.
  14. European Medicines Agency, Guideline on registry-based studies – Scientific guideline. 2021.
  15. RIZIV-INAMI. Hervorming terugbetalingsprocedures geneesmiddelen. 2025; Available from: https://www.inami.fgov.be/nl/thema-s/verzorging-kosten-en-terugbetaling/wat-het-ziekenfonds-terugbetaalt/geneesmiddelen/hervorming-terugbetalingsprocedures-geneesmiddelen.
  16. Zorginstituut Nederland. Weesgeneesmiddelenarrangement. Available from: https://www.zorginstituutnederland.nl/wat-wij-doen/werkwijzen-en-procedures/adviseren-over-en-verduidelijken-van-het-basispakket-aan-zorg/beoordeling-van-geneesmiddelen/weesgeneesmiddelarrangementen.

 

Our expertise:

Related articles

Get in touch

Contact us to discover more about Kintiga and how we can help shape a future of impactful, patient-focused solutions across Europe.

Scroll to Top